Dr. Buchbinder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1001 Potrero Avenue
RM 5H22
San Francisco, CA 94110Phone+1 415-206-8317Fax+1 415-476-8965
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1985 - 1988- University of California San Francisco School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1987 - 2027- American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Study of the Effects of Advantage 24 on the Rectum
- A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1 Start of enrollment: 1999 Aug 01
- Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men Start of enrollment: 2005 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsDoxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends.Madeline Sankaran, David V Glidden, Robert P Kohn, Trang Q Nguyen, Oliver Bacon
JAMA Internal Medicine. 2025-01-06 - 2 citationsAntiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.Rajesh T Gandhi, Raphael J Landovitz, Paul E Sax, Davey M Smith, Sandra A Springer
JAMA. 2024-12-01 - Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease.Alton Barbehenn, Lei Shi, Junzhe Shao, Rebecca Hoh, Heather M Hartig
Nature Communications. 2024-11-18
Journal Articles
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsMichael S Saag, Melanie A Thompson, Constance A Benson, Susan P Buchbinder, Joseph J Eron, Donna M Jacobsen, JAMA
Press Mentions
HIV Vaccine Research Update with Dr. Dieffenbach from CROI 2023February 22nd, 2023- Why Inventing a Vaccine for AIDS Is Tougher Than for COVIDJanuary 26th, 2023
- A Promising HIV Vaccine Just Failed an Important Clinical TrialJanuary 20th, 2023
- Join now to see all
Grant Support
- Prevention Umbrella For MSM In The AmericasNational Institute Of Allergy And Infectious Diseases2009–2012
- SAN Francisco Vaccine And Prevention UnitNational Institute Of Allergy And Infectious Diseases2007–2012
- SAN Francisco HIV Vaccine Clinical Trails UnitNational Institute Of Allergy And Infectious Diseases2000–2006
- Phase II Extended Safety Study Of Tenofovir Disoproxil Fumarate (TDF) Among HNational Center For Research Resources2005
- HVTN Protocol 056, Version 1: A Phase I Clinical Trial To Evaluate The Safety AnNational Center For Research Resources2005
- HVTN Protocol 042/Anrs Vac019, Version 1: A Phase I/II Clinical TrialNational Center For Research Resources2005
- HVTN 057: A Phase I Clinical Trial To Evaluate The Safety Of A Multiclade RECNational Center For Research Resources2005
- HVTN 052: HIV-1 DNA Plasmid Vaccine At 2 Different Dosings In Hiv-1-Uninfected ANational Center For Research Resources2005
- HVTN 050/Merck 018safety, Tolerability, And Immunogenicity Of Mrkad5 HIV-1 GAG VNational Center For Research Resources2005
- Safety, Tolerability, And Immunogenicity Of Mrkad5 HIV-1 GAG VaccineNational Center For Research Resources2004
- HIV-1 Pga2/Js2 Plasmid DNA Vaccine In HIV-1 Uninfected AdultsNational Center For Research Resources2004
- HIV-1 DNA Plasmid Vaccine At 2 Different Dosings In Hiv-1-Uninfected AdultsNational Center For Research Resources2004
- Trial Of Live (PRIVATE) Recombinant Canarypox Alva-Hiv Vcp205 In HIVNational Center For Research Resources1998–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
